Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Active Reference, Parallel-Group Polysomnography Study to Assess the Efficacy and Safety of a 16-Day Oral Administration of ACT-078573 [almorexant] in Adult Subjects With Chronic Primary Insomnia

Trial Profile

Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Active Reference, Parallel-Group Polysomnography Study to Assess the Efficacy and Safety of a 16-Day Oral Administration of ACT-078573 [almorexant] in Adult Subjects With Chronic Primary Insomnia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Almorexant (Primary) ; Zolpidem
  • Indications Insomnia
  • Focus Registrational; Therapeutic Use
  • Acronyms RESTORA; RESTORA-1
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 15 Mar 2012 According to EudraCT this trial is ongoing in Slovakia, Spain, United Kingdom, France and NCT reports trial status as completed. I have retained NCT because it is consistent with MR.
    • 15 Mar 2012 Additional location (England) added as reported by European Clinical Trials Database.
    • 05 Feb 2010 Actual end date changed from Oct 2009 to Nov 2009 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top